First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
ChromaDex Corporation (CDXC)
NASDAQ:AMEX Investor Relations:
investors.chromadex.com
Company Research
Source: GlobeNewswire
LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise therapy in older adults with hypertension. ChromaDex’s patent-protected NR is a unique form of vitamin B3 that is proven to safely increase NAD+ levels in the body. NAD+ declines as we age and is a critical coenzyme for cellular energy production and mitochondrial function, both important components of healthy human aging. About one third of U.S. adults have hypertension, putting them at greater risk of cardiovascular disease, or even death. The benefits of exercise in helping to manage hypertension and enhance cardiovascular health are
Show less
Read more
Impact Snapshot
Event Time:
CDXC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXC alerts
High impacting ChromaDex Corporation news events
Weekly update
A roundup of the hottest topics
CDXC
News
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® [Yahoo! Finance]Yahoo! Finance
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®Business Wire
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024Business Wire
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketBusiness Wire
CDXC
Earnings
- 3/6/24 - Beat
CDXC
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- CDXC's page on the SEC website